Bharat Pothuri, MD
Gastroenterology · Houston, TXNPI 1023187614
Payments from drug & device makers
Across 249 payments — averaging $62.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$10K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$875
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$478
- Boston Scientific$447
- Bristol Myers Squibb$430
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$9,46060%
- Food & beverage$6,19040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 15 | $10,144 |
| AbbVie(2 entities) | 54 | $1,079 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $875 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $478 |
| Boston Scientific | 5 | $447 |
| Bristol Myers Squibb | 28 | $430 |
| Braintree Laboratories, Inc. | 10 | $217 |
| Sanofi | 10 | $217 |
| Gilead | 4 | $165 |
| Johnson & Johnson(2 entities) | 6 | $150 |
| QOL Medical, LLC | 8 | $142 |
| Redhill Biopharma Inc. | 6 | $118 |
| Intercept Pharmaceuticals, Inc. | 2 | $118 |
| Merck | 6 | $117 |
| GSK | 1 | $108 |
| Lilly USA, LLC | 4 | $107 |
| E.r. Squibb & Sons, L.L.C. | 1 | $104 |
| Ardelyx, Inc. | 4 | $76 |
| Conmed Corporation | 3 | $58 |
| Pfizer | 3 | $55 |
| Ferring Pharmaceuticals Inc. | 3 | $51 |
| Ironwood Pharmaceuticals, Inc | 2 | $42 |
| Medtronic | 2 | $40 |
| Shire North American Group Inc | 2 | $38 |
| AstraZeneca(2 entities) | 2 | $38 |
| Covidien LP | 1 | $38 |
| Evoke Pharma, Inc. | 2 | $35 |
| Enterra Medical, Inc. | 1 | $27 |
| Mauna Kea Technologies, Inc. | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Celltrion USA Inc. | 1 | $21 |
| Romark Laboratories, LC | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Cook Medical LLC | 1 | $16 |
| Pentax Of America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$10,052
- GENERAL - THERAPIES$267
- Epclusa$122
- ORISE$118
- TRELEGY ELLIPTA$108
- ZEPOSIA$104
How this compares
$15,650 in reported general payments places this provider in the 80th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 26 | $35,092 |
| CreonLipase/Protease/Amylase | 12 | $15,837 |
| TrulancePlecanatide | 12 | $7,552 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 79 | $4,758 |
| Mesalamine | 13 | $4,526 |
| CholestyramineCholestyramine (With Sugar) | 22 | $3,362 |
| Esomeprazole Magnesium | 45 | $3,237 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 201 | $2,635 |
| Pantoprazole Sodium | 191 | $2,509 |
| Famotidine | 143 | $1,859 |
| Ursodiol | 12 | $1,518 |
| Omeprazole | 129 | $1,442 |
| Lactulose | 53 | $1,183 |
| Sucralfate | 16 | $840 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 59 | $715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $1,079 | $50,92938 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $478 | $7,55212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Mazen NoureddinHouston$6.1M
- James MaherHouston$5.3M
- Uma MohanHouston$5M
- John VierlingHouston$2.8M
- Bincy AbrahamHouston$2.5M
- Jason HouHouston$2.3M
- Jignesh ShahHouston$1.7M
- Mouhamad Al-SabbaghHouston$1.6M
- Mohamed OthmanHouston$1.6M
- Harry OjeasHouston$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.